Search





Search





Markets
/
Stocks
/
wve
/

WAVE Life Sciences Ltd

WVE

Add to Watchlist

5.510USD

-0.250-4.34%

Close 07-31 16:00（ET）Quotes delayed by 15 min

1.09BMarket Cap

LossP/E TTM

WAVE Life Sciences Ltd

5.510

-0.250-4.34%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

-4.34%

5 Days

-5.16%

1 Month

-11.98%

6 Months

-58.97%

Year to Date

-67.59%

1 Year

-36.15%

Key Figures

5.650Open

5.750High

2.87MVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

1.48%Turnover Ratio

5.760Prev. Close

5.370Low

11.85MTurnover

LossP/E Static

2.35P/B

0.00%Div Yield TTM

-42.11%ROA

21.73052wk High

1.11Volume Ratio

-97.01MNet Profit

193.28MShares

-1.0537EPS TTM

-1.16Beta

-53.72%ROE

5.02052wk Low

6.60%Amplitude

100.00%Gross Margin

1.09BMarket Cap

-1.81Reward/Risk

4.89%Risk Rate

TradingKey Stock Score of WAVE Life Sciences Ltd

Currency: USD Updated: 2026-07-31

Key Insights

WAVE Life Sciences Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 35 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

WAVE Life Sciences Ltd's Score

Industry at a Glance

Industry Ranking

35 / 385

Overall Ranking

100 / 4281

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

WAVE Life Sciences Ltd Highlights

StrengthsRisks

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).

Growing

The company is in a growing phase, with the latest annual income totaling USD 42.73M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 42.73M.

Overvalued

The company’s latest PE is -5.23, at a high 3-year percentile range.

Held by Lee Ainslie

Star Investor Lee Ainslie holds 11.62M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.15.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

20.813

Target Price

+277.72%

Upside Space

WAVE Life Sciences Ltd News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 16 analysts

Buy

Current Rating

20.813

Target Price

+277.72%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

496

Total

Median

Average

Company name

Ratings

Analysts

WAVE Life Sciences Ltd

WVE

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Kymera Therapeutics Inc

KYMR

...

Indicators

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.030

Sell

RSI(14)

37.328

Neutral

STOCH(KDJ)(9,3,3)

33.836

Sell

ATR(14)

0.253

High Vlolatility

CCI(14)

-177.058

Sell

Williams %R

81.935

Oversold

TRIX(12,20)

-0.194

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

5.778

Sell

MA10

5.774

Sell

MA20

5.936

Sell

MA50

5.980

Sell

MA100

7.187

Sell

MA200

9.602

Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

WAVE Life Sciences Ltd Info

Ticker SymbolWVE

CompanyWAVE Life Sciences Ltd

CEOBolno (Paul B)

Websitehttps://www.wavelifesciences.com/

Shareholders

Shareholders

Proportion

RA Capital Management, LP

14.02%

GSK plc

9.48%

Fidelity Management & Research Company LLC

7.10%

BlackRock Institutional Trust Company, N.A.

5.21%

Adage Capital Management, L.P.

5.09%

Other

59.11%

Popular Instruments

FAQs

What is the current price of WAVE Life Sciences Ltd (WVE)?



The current price of WAVE Life Sciences Ltd (WVE) is 5.51.

What is the symbol of WAVE Life Sciences Ltd?



The ticker symbol of WAVE Life Sciences Ltd is WVE.

What is the 52-week high of WAVE Life Sciences Ltd?



The 52-week high of WAVE Life Sciences Ltd is 21.73.

What is the 52-week low of WAVE Life Sciences Ltd?



The 52-week low of WAVE Life Sciences Ltd is 5.02.

What is the market capitalization of WAVE Life Sciences Ltd?



The market capitalization of WAVE Life Sciences Ltd is 1.09B.

Is WAVE Life Sciences Ltd (WVE) currently rated as Buy, Hold, or Sell?



According to analysts, WAVE Life Sciences Ltd (WVE) has an overall rating of Buy, with a price target of 20.81.

What is the Earnings Per Share (EPS TTM) of WAVE Life Sciences Ltd (WVE)?



The Earnings Per Share (EPS TTM) of WAVE Life Sciences Ltd (WVE) is -1.21.